U.S. Auto Components Stock News

Pentair plc ( NYSE:PNR ) has announced that it will be increasing its dividend from last year's comparable payment on...

Key Insights Mega Fortune's estimated fair value is US$9.33 based on 2 Stage Free Cash Flow to Equity With US$8.78...

What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...

The Manitowoc Company, Inc. ( NYSE:MTW ) shares have continued their recent momentum with a 25% gain in the last month...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

We note that the Johnson Outdoors Inc. ( NASDAQ:JOUT ) Independent Director, Edward Lang, recently sold US$88k worth of...

Anyone interested in White Mountains Insurance Group, Ltd. ( NYSE:WTM ) should probably be aware that the Independent...

DXC Technology Company ( NYSE:DXC ) shareholders would be excited to see that the share price has had a great month...

The board of CVB Financial Corp. ( NASDAQ:CVBF ) has announced that it will pay a dividend of $0.20 per share on the...

Benchmark Electronics, Inc. ( NYSE:BHE ) has announced that it will pay a dividend of $0.17 per share on the 13th of...

The Estée Lauder Companies Inc. ( NYSE:EL ) shareholders have had their patience rewarded with a 26% share price jump...

Quad/Graphics, Inc. ( NYSE:QUAD ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...

We wouldn't blame World Acceptance Corporation ( NASDAQ:WRLD ) shareholders if they were a little worried about the...

FMC Corporation ( NYSE:FMC ) is reducing its dividend from last year's comparable payment to $0.08 on the 15th of...

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

eHealth, Inc. ( NASDAQ:EHTH ) shareholders would be excited to see that the share price has had a great month, posting...

Monte Rosa Therapeutics (GLUE) just gave investors a fresh catalyst, sharing interim Phase 1/2 data showing 100% disease control and PSA responses in a key prostate cancer subgroup, along with plans for a follow up Phase 2 trial. See our latest analysis for Monte Rosa Therapeutics. That strength in the clinic has gone hand in hand with shifting sentiment in the stock, with a 150.08% 3 month share price return and 128.43% 1 year total shareholder return signaling powerful, still building...

Earlier this quarter, Belden reported record third-quarter revenue and adjusted earnings per share, beating analyst expectations and delivering stronger-than-anticipated operating income and Enterprise segment performance. Riverwater Partners’ latest Small Cap Strategy letter emphasized CEO Dr. Ashish Chand’s solutions-focused networking approach and Horizon software platform as key drivers of Belden’s consistent high single-digit revenue growth and double-digit adjusted EPS gains,...

Workday (WDAY) is back in the spotlight after unveiling fresh partnerships that deepen its compensation and AI agent ecosystem, moves that matter less for today’s share price and more for its long term platform stickiness. See our latest analysis for Workday. That backdrop of new partnerships lands at a tricky moment for sentiment, with the share price at $218.08 after a soft recent stretch, including a negative year to date share price return and a weaker 1 year total shareholder return,...

Earlier this week, reports that the House Speaker would not allow a vote on renewing Affordable Care Act premium subsidies raised fresh concerns about Centene’s ACA marketplace exposure and the broader pressure of rising medical costs on health insurers’ profitability. At the same time, Centene’s Ambetter Health and Sunshine Health units have been rolling out community-focused partnerships with professional and elite athletes, highlighting the company’s emphasis on preventive care, Medicaid...

Virtu Financial (VIRT) has quietly lagged the market this year, even though its longer term returns remain strong. That gap between recent weakness and multi year strength is what makes the stock interesting now. See our latest analysis for Virtu Financial. Over the past year, Virtu’s modest 1 year total shareholder return decline contrasts with its strong three and five year total shareholder returns. This suggests momentum has cooled lately even as the long term story still looks intact at...

Rapport Therapeutics recently reported new data and post hoc analyses from its Phase 2a trial of RAP-219 in drug-resistant focal onset seizures, presented at the 2025 American Epilepsy Society Meeting, highlighting statistically significant improvements in several seizure-related patient-reported outcomes and confirming target engagement in key brain regions. The company also outlined plans for an end-of-Phase 2 meeting with the FDA and the potential launch of two pivotal Phase 3 trials in...

Earlier in December 2025, Ocular Therapeutix said it now plans to file a New Drug Application for its wet AMD candidate AXPAXLI (OTX-TKI) based on positive year-one data from the ongoing SOL-1 Phase 3 trial, with those data expected in the first quarter of 2026. This shift reflects recent feedback and public comments from the FDA that could allow AXPAXLI to pursue approval using a single pivotal trial and the 505(b)(2) pathway, potentially shortening the route to market if results support...

Strategic moves reshape the outlook for Noble stock Noble (NE) just set a new course by agreeing to sell six jackup rigs, doubling down on deepwater and ultra harsh environments, while its Globetrotter I drillship reaches the Black Sea and a major bank issues a downgrade. See our latest analysis for Noble. Those portfolio moves and the downgrade are landing against a weak backdrop, with the share price down sharply on a year to date basis. Yet a modestly positive 1 year total shareholder...